Do analysts recommend ORMP or DBVT?

DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 298.52%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 DBV Technologies 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts rate ORMP or PHAR?

Pharming Group has a consensus price target of $38.67, indicating a potential upside of 259.02%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pharming Group 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Do analysts rate ORMP or NVCT?

Nuvectis Pharma has a consensus target price of $36.25, indicating a potential upside of 72.05%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable valuation & earnings, ORMP or NVCT?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oramed Pharmaceuticals N/A N/A $64.05M $4.12 1.15 Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is ORMP or NVCT more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Nuvectis Pharma N/A -184.25% -105.24%

Do analysts recommend ANNX or ORMP?

Annexon currently has a consensus target price of $15.14, suggesting a potential upside of 291.29%. Given Annexon's stronger consensus rating and higher possible upside, analysts clearly believe Annexon is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 2 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.40 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, ANNX or ORMP?

Annexon is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Oramed Pharmaceuticals N/A N/A $64.05M $4.12 1.15

Is ANNX or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Oramed Pharmaceuticals N/A -5.17% -4.54%

Oramed Pharmaceuticals (ORMP) Competitors

$4.72 -0.03 (-0.63%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.72 0.00 (0.00%)

As of 09/23/2026 04:15 PM Eastern

Compare

ORMP vs. DBVT, PHAR, NVCT, FDMT, and ANNX

Should you buy Oramed Pharmaceuticals stock or one of its competitors? Oramed Pharmaceuticals's main competitors and comparable companies include DBV Technologies (DBVT), Pharming Group (PHAR), Nuvectis Pharma (NVCT), 4D Molecular Therapeutics (FDMT), and Annexon (ANNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oramed Pharmaceuticals compare to DBV Technologies?

Oramed Pharmaceuticals (NASDAQ:ORMP) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Oramed Pharmaceuticals has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.15
DBV Technologies	$5.64M	135.68	-$146.95M	-$3.51	N/A

In the previous week, DBV Technologies had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for DBV Technologies and 0 mentions for Oramed Pharmaceuticals. DBV Technologies' average media sentiment score of 0.71 beat Oramed Pharmaceuticals' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
DBV Technologies	Positive

DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 298.52%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Oramed Pharmaceuticals has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Oramed Pharmaceuticals' return on equity of -5.17% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oramed Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, indicating that its share price is 195% less volatile than the broader market.

Summary

Oramed Pharmaceuticals beats DBV Technologies on 8 of the 15 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Pharming Group?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Pharming Group has a net margin of 2.51% compared to Oramed Pharmaceuticals' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Pharming Group	2.51%	3.40%	1.90%

Oramed Pharmaceuticals has higher earnings, but lower revenue than Pharming Group. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.15
Pharming Group	$376.13M	2.03	$2.85M	$0.12	89.75

Oramed Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Pharming Group has a consensus price target of $38.67, indicating a potential upside of 259.02%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Pharming Group had 6 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for Pharming Group and 0 mentions for Oramed Pharmaceuticals. Pharming Group's average media sentiment score of 0.60 beat Oramed Pharmaceuticals' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Pharming Group	Positive

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Pharming Group beats Oramed Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Nuvectis Pharma?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

In the previous week, Nuvectis Pharma had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for Nuvectis Pharma and 0 mentions for Oramed Pharmaceuticals. Nuvectis Pharma's average media sentiment score of 0.08 beat Oramed Pharmaceuticals' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Nuvectis Pharma	Neutral

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oramed Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.15
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Nuvectis Pharma has a consensus target price of $36.25, indicating a potential upside of 72.05%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Oramed Pharmaceuticals' return on equity of -5.17% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Summary

Nuvectis Pharma beats Oramed Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

4D Molecular Therapeutics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. Oramed Pharmaceuticals' return on equity of -5.17% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 0 mentions for Oramed Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 0.58 beat Oramed Pharmaceuticals' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
4D Molecular Therapeutics	Positive
Oramed Pharmaceuticals	Neutral

4D Molecular Therapeutics presently has a consensus target price of $28.56, indicating a potential upside of 90.37%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$92.01M	9.01	-$140.11M	-$2.63	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.15

Summary

4D Molecular Therapeutics beats Oramed Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Annexon?

Annexon (NASDAQ:ANNX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Annexon has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

In the previous week, Annexon had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for Annexon and 0 mentions for Oramed Pharmaceuticals. Annexon's average media sentiment score of 0.37 beat Oramed Pharmaceuticals' score of 0.00 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Neutral
Oramed Pharmaceuticals	Neutral

Oramed Pharmaceuticals' return on equity of -5.17% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Annexon is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.15

Annexon currently has a consensus target price of $15.14, suggesting a potential upside of 291.29%. Given Annexon's stronger consensus rating and higher possible upside, analysts clearly believe Annexon is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Oramed Pharmaceuticals beats Annexon on 7 of the 13 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$197.59M	$3.98B	$7.31B	$13.29B
Dividend Yield	5.32%	3.63%	2.52%	12.57%
P/E Ratio	1.15	13.88	274.07	25.69
Price / Sales	N/A	1,356.95	643.13	79.17
Price / Cash	52.36	113.29	77.80	52.76
Price / Book	0.94	15.40	10.47	6.32
Net Income	$64.05M	-$22.82M	$3.49B	$359.73M
7 Day Performance	1.07%	-1.71%	-0.67%	0.17%
1 Month Performance	-2.07%	-6.18%	-3.17%	-3.27%
1 Year Performance	96.67%	30.64%	15.13%	5.58%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	1.5479 of 5 stars	$4.72 -0.6%	N/A	+89.6%	$197.59M	N/A	1.15	13
DBVT DBV Technologies	3.4461 of 5 stars	$11.76 -4.8%	$48.50 +312.4%	+30.2%	$776.54M	$5.64M	N/A	161
PHAR Pharming Group	4.3498 of 5 stars	$10.55 -2.5%	$38.67 +266.5%	-27.1%	$765.82M	$376.13M	87.92	407	Analyst Forecast
NVCT Nuvectis Pharma	3.5145 of 5 stars	$21.92 -6.1%	$36.25 +65.4%	+251.2%	$762.24M	N/A	N/A	13	Analyst Upgrade
FDMT 4D Molecular Therapeutics	3.1303 of 5 stars	$13.63 -0.9%	$28.56 +109.5%	+97.1%	$760.16M	$85.21M	N/A	196

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. DBVT, PHAR, NVCT, FDMT, and ANNX

How does Oramed Pharmaceuticals compare to DBV Technologies?

Summary

How does Oramed Pharmaceuticals compare to Pharming Group?

Summary

How does Oramed Pharmaceuticals compare to Nuvectis Pharma?

Summary

How does Oramed Pharmaceuticals compare to 4D Molecular Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. DBVT, PHAR, NVCT, FDMT, and ANNX

How does Oramed Pharmaceuticals compare to DBV Technologies?

Which has preferable valuation & earnings, ORMP or DBVT?

Does the media refer more to ORMP or DBVT?

Do analysts recommend ORMP or DBVT?

Is ORMP or DBVT more profitable?

Do institutionals & insiders believe in ORMP or DBVT?

Which has more volatility & risk, ORMP or DBVT?

Summary

How does Oramed Pharmaceuticals compare to Pharming Group?

Is ORMP or PHAR more profitable?

Which has stronger valuation & earnings, ORMP or PHAR?

Which has more volatility & risk, ORMP or PHAR?

Do analysts rate ORMP or PHAR?

Does the media refer more to ORMP or PHAR?

Do insiders and institutionals believe in ORMP or PHAR?

Summary

How does Oramed Pharmaceuticals compare to Nuvectis Pharma?

Does the media prefer ORMP or NVCT?

Do insiders and institutionals have more ownership in ORMP or NVCT?

Which has more risk and volatility, ORMP or NVCT?

Which has preferable valuation & earnings, ORMP or NVCT?

Do analysts rate ORMP or NVCT?

Is ORMP or NVCT more profitable?

Summary

How does Oramed Pharmaceuticals compare to 4D Molecular Therapeutics?

Which has more volatility and risk, FDMT or ORMP?

Do insiders & institutionals have more ownership in FDMT or ORMP?

Is FDMT or ORMP more profitable?

Does the media refer more to FDMT or ORMP?

Do analysts recommend FDMT or ORMP?

Which has higher earnings and valuation, FDMT or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Annexon?

Which has more volatility and risk, ANNX or ORMP?

Does the media prefer ANNX or ORMP?

Is ANNX or ORMP more profitable?

Which has better earnings and valuation, ANNX or ORMP?

Do analysts recommend ANNX or ORMP?

Do insiders & institutionals hold more shares of ANNX or ORMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools